Last reviewed · How we verify
Liposomal cytarabine-daunorubicin for injection
Liposomal cytarabine-daunorubicin for injection is a Liposomal chemotherapy combination Small molecule drug developed by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. It is currently in Phase 3 development for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Lymphomatous meningitis.
This liposomal formulation delivers cytarabine and daunorubicin directly into leukemic cells, where both drugs inhibit DNA synthesis and induce apoptosis.
This liposomal formulation delivers cytarabine and daunorubicin directly into leukemic cells, where both drugs inhibit DNA synthesis and induce apoptosis. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Lymphomatous meningitis.
At a glance
| Generic name | Liposomal cytarabine-daunorubicin for injection |
|---|---|
| Sponsor | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. |
| Drug class | Liposomal chemotherapy combination |
| Target | DNA polymerase (cytarabine); Topoisomerase II (daunorubicin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cytarabine is a nucleoside analog that inhibits DNA polymerase and blocks DNA synthesis, while daunorubicin is a topoisomerase II inhibitor that causes DNA strand breaks. The liposomal encapsulation allows preferential uptake by leukemic blasts, particularly in the central nervous system, improving drug delivery and reducing systemic toxicity to normal tissues.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Lymphomatous meningitis
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Infection
- Cardiotoxicity
- Neurotoxicity (cytarabine syndrome)
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) (PHASE2)
- Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- Tazemetostat and Palbociclib With CPX-351for R/R AML (PHASE1)
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (PHASE2)
- CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia (PHASE2)
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (PHASE3)
- CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal cytarabine-daunorubicin for injection CI brief — competitive landscape report
- Liposomal cytarabine-daunorubicin for injection updates RSS · CI watch RSS
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. portfolio CI
Frequently asked questions about Liposomal cytarabine-daunorubicin for injection
What is Liposomal cytarabine-daunorubicin for injection?
How does Liposomal cytarabine-daunorubicin for injection work?
What is Liposomal cytarabine-daunorubicin for injection used for?
Who makes Liposomal cytarabine-daunorubicin for injection?
What drug class is Liposomal cytarabine-daunorubicin for injection in?
What development phase is Liposomal cytarabine-daunorubicin for injection in?
What are the side effects of Liposomal cytarabine-daunorubicin for injection?
What does Liposomal cytarabine-daunorubicin for injection target?
Related
- Drug class: All Liposomal chemotherapy combination drugs
- Target: All drugs targeting DNA polymerase (cytarabine); Topoisomerase II (daunorubicin)
- Manufacturer: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute myeloid leukemia (AML)
- Indication: Drugs for Acute lymphoblastic leukemia (ALL)
- Indication: Drugs for Lymphomatous meningitis
- Compare: Liposomal cytarabine-daunorubicin for injection vs similar drugs
- Pricing: Liposomal cytarabine-daunorubicin for injection cost, discount & access